Comparative evaluation of immunogenicity and reactogenicity of monovalent type 2 and 3 oral poliovirus vaccines (mOPV 2 and mOPV3) versus trivalent oral poliovirus vaccine (tOPV), and bivalent oral poliovirus vaccine (bOPV) versus monovalent types 1 and 3 oral poliovirus vaccines, respectively: a randomised double-blind trial

Panacea Biotec Limited (India)0 个研究点目标入组 900 人开始时间: 2008年11月26日最近更新: 2015年1月13日

试验速览

暂无简介。

•1. Healthy newborns (either sex) (greater than or equal to 2.50 kg birth weight, apgar score at 5 min greater than or equal to 9) at the study sites (large maternity hospitals)
•2. Residing within a relatively short and easily accessible distance (less than 30 km)
•3. Not planning to travel away during entire the study period (birth - 2 months)

•1. Newborns requiring hospitalisation
•2. Birth weight below 2.50 kg
•3. Apgar score at 5 min less than 9
•4. Residence greater than 30 km from study site
•5. Families expecting to be absent during the 60-day study period
•6. A diagnosis or suspicion of immunodeficiency disorder (either in the participant or in a member of the immediate family) will render the newborn ineligible for the study

发起方

Panacea Biotec Limited (India)